FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  LUDVIGSON DAVID
2. Date of Event Requiring Statement (Month/Day/Year)
06/04/2021
3. Issuer Name and Ticker or Trading Symbol
Boston Therapeutics, Inc. [BTHE]
(Last)
(First)
(Middle)
C/O BOSTON THERAPEUTICS, INC., 5900 HOLLIS STREET
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO and President
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

EMERYVILLE, CA 95608
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.0001 par value per share 0
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock (1) 06/04/2021   (1) Common Stock, $0.0001 par value per share 58,316,292 $ (1) D  
Warrants (2) 06/04/2021 06/04/2026 Common Stock, $0.0001 par value per share 6,503,659 $ 0.0034 D  
Restricted Stock Units (3) 06/04/2021 06/04/2031 Common Stock, $0.0001 par value per share 181,809,374 $ 0 D  
Incentive Stock Options (4) 11/30/2012 11/30/2022 Common Stock, $0.0001 par value per share 7,218,039 $ 0.0003 D  
Incentive Stock Options (4) 03/31/2014 03/31/2024 Common Stock, $0.0001 par value per share 96,742,608 $ 0.0014 D  
Incentive Stock Options (4) 10/04/2016 10/04/2026 Common Stock, $0.0001 par value per share 14,916,033 $ 0.0014 D  
Incentive Stock Options (4) 05/31/2017 05/31/2027 Common Stock, $0.0001 par value per share 14,730,691 $ 0.0014 D  
Incentive Stock Options (4) 02/11/2020 02/11/2030 Common Stock, $0.0001 par value per share 22,096,037 $ 0.0017 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
LUDVIGSON DAVID
C/O BOSTON THERAPEUTICS, INC.
5900 HOLLIS STREET
EMERYVILLE, CA 95608
  X     CEO and President  

Signatures

/s/ David Ludvigson 06/30/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of Series C Preferred Stock has a stated value of $1.00 per share and is convertible into shares of common stock at a conversation rate of 6,066.044596 shares of common stock for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are automatically converted upon the filing of an amendment to the Company's certificate of incorporation implementing a reverse stock split.
(2) The shares underlying the warrants and the RSU may not be exercised until the implementation of a reverse stock split.
(3) RSUs vesting over 2 years
(4) Previously issued ISO stock options vested and unvested

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.